Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

1

Post-transplant cyclophosphamide (PTCy) combined with everolimus shows promise as a GvHD prophylaxis in refractory lymphoma patients.
2

The OCTET-EVER trial demonstrated low rates of GvHD and non-relapse mortality (NRM) with a GRFS of 42% and OS of 64% at two years.
3

Acute GvHD occurred in 63.6% of patients, with 33.3% experiencing grade II and 6.1% experiencing grade III and IV.
4

Median overall survival (OS) was 64% at one and two years, with progression-free survival (PFS) at 58% and 55% respectively.
5

The study supports the efficacy of PTCy and everolimus, highlighting the need for improved immunosuppressive strategies in high-risk lymphoma patients.

Bone Marrow Transplantation

by Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel, Philipp Gödel, Moritz Fürstenau, Pascal Nieper, Till Braun, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick
November 15, 2024

1